🚨 Exciting News! 🚨 Our ECG-powered aortic stenosis AI screening tool has received FDA Breakthrough Device Designation! This recognition marks a major milestone in our mission to expand the use of ECGs as a broad biomarker. By enabling earlier detection and better management of aortic stenosis, a critical heart condition often missed in routine care, we’re contributing to our goal of improving patient outcomes and saving lives globally. A huge thank you to the AccurKardia team for their hard work in making this happen. Special thanks to the The Texas Heart Institute team for their mentorship, and the Mayo Clinic Platform_Accelerate team, whose program expedited our clinical validation efforts. Also, a big thank you to Erik Swain and the team at Healio for covering this important achievement. Check out the full story here: https://lnkd.in/dYJ6w4JN. Stay tuned for more updates as we continue to advance the future of care, one ECG at a time. 💙 cc: Juan C Jimenez, Mohamed Sadeq Ali, Moin Hussaini, Nav Razvi, Tony M Kuttiachen, John Fox, Naveen Srinivas #ECG #CardiovascularHealth #AI #AorticStenosis #DigitalHealth #BetterOutcomes
About us
AccurKardia is an ECG-led diagnostics software company transforming ECG signals into a broad biomarker and diagnostic tool for disease management in cardiology and beyond. Our mission is to improve patient outcomes and save lives on a global scale. Our flagship product, AccurECG™, is an FDA-cleared (Class II SaMD), cloud-based, device-agnostic software providing fully automated ECG interpretation, capable of detecting up to 13 arrhythmias. It assists cardiac monitoring companies in analyzing ECGs from holters, event recorders, and cardiac telemetry devices, significantly enhancing efficiency and patient care. Recently, AccurKardia reached a major milestone with the FDA Breakthrough Device Designation for our AI-driven ECG-based Aortic Valve Stenosis (AK-AVS) screening software. This achievement highlights our dedication to advancing early detection and precision medicine in cardiovascular care. We are also proud participants in the MedTech Innovator 2024 Cohort and the Heart & Brain Health Accelerator track, in collaboration with the American Heart Association’s Center for Health Technology and Innovation.
- Website
-
http://www.accurkardia.com
External link for AccurKardia
- Industry
- Software Development
- Company size
- 11-50 employees
- Headquarters
- New York, NY
- Type
- Privately Held
- Founded
- 2019
- Specialties
- artificial intelligence, AI, cardiac healthcare, ecg analysis, healthtech, medtech, IoT, digitalhealth, medical devices, remote patient monitoring, diagnostics, biomarker, and EKG
Locations
-
Primary
Get directions
101 Avenue of the Americas
New York, NY 10013, US
Employees at AccurKardia
Updates
-
Healthcare Disparities in Aortic Stenosis Diagnosis and Treatment A recent study in JACC: Advances examines how residential racial segregation affects aortic stenosis (AS) diagnosis and transcatheter aortic valve implantation (TAVI) rates among Medicare patients. The results reveal significant disparities in care access, particularly for Black patients in highly segregated areas. Learn more: https://lnkd.in/e6gFN4Qs We are addressing this inequity with AK-AVS, our AI-powered, non-invasive diagnostic tool for AS. By leveraging widely available ECG data, AK-AVS enables scalable, early detection and helps ensure equitable access to care across all zip codes in America.
Residential Racial Segregation in Aortic Stenosis Diagnosis and Transcatheter Aortic Valve Implantation Among Medicare Patients:
jacc.org
-
In a recent Medsider interview with Scott Nelson our CEO, Juan C Jimenez, shared how AccurKardia is transforming medtech innovation through a lean, strategic approach and relentless execution. Scott captured this concept perfectly: 💡 “If 80% of your capital goes to commercialization instead of development, ROI is exponentially stronger.” With our FDA-cleared AccurECG™ and Breakthrough Device Designation for AK-AVS™, we’re proving that impactful results come from smart execution. Check out the full interview to discover how we’re driving innovation and better patient outcomes.
“If you're staring down $50 million in capital to get to a point where you're actually selling product, if 80% of that capital was used in the development versus maybe the opposite, where 80% is now being used to commercialize it, there's going to be a much stronger ROI in the latter scenario.” Meet Juan C Jimenez, a former investment banker and previous President of Puerto Rico’s largest non-emergency medical transportation company, TransCita, now bringing his fresh perspectives to #medtech. Juan co-founded AccurKardia with a mission to streamline ECG interpretation and make cardiac diagnostics more accessible and efficient with AI. AccurKardia’s platform is designed to fully automate ECG interpretation, reducing time and costs for cardiac monitoring companies. Their flagship product, AccurECG, has earned FDA 510(k) clearance, too. Here's a sneak peek at Juan’s conversation with Scott Nelson: 💸 Capital efficiency can often be more valuable than flashy, oversized funding rounds. Focus on scaling sustainably without unnecessary dilution by keeping your organization lean and focused. 🛠️ Focus on developing your product and thoroughly understanding your market before inviting investors to join your venture. Allow your team space to develop a solid foundation before bringing in external opinions to ensure that early investor feedback doesn’t misalign or dilute your core vision. 🤝 Prioritize genuine relationships, transparency, and rigorous standards to build credibility and lasting partnerships. Be upfront about both your strengths and limitations and embrace a proactive approach to validation. Click the link in the comments for the full interview. This Medsider episode was brought to you by FastWave Medical, a hot IVL startup in the cardiovascular space. Don’t miss out on their next fundraise (more details in the comments). P.S. - We recently launched Medsider Mentors Volume VI, which is packed with insights and learnings from founders and CEOs of some of the most dynamic medical device and health technology startups in the world. Click the link in the comment section for this latest edition now available exclusively to our premium members.
-
A recent publication by the American Heart Association Presidential Advisory Group projects that annual U.S. healthcare costs for cardiovascular diseases could escalate from $400 billion in 2020 to $1.344 trillion by 2050. At AccurKardia, we're dedicated to improving patient outcomes and saving lives, which in turn helps mitigate this economic burden. Our advanced, device-agnostic ECG analytics enable early detection and proactive management of cardiac conditions, aiming to reduce costs through predictive capabilities. https://lnkd.in/gcJriiSP
Forecasting the Economic Burden of Cardiovascular Disease and Stroke in the United States Through 2050: A Presidential Advisory From the American Heart Association | Circulation
ahajournals.org
-
AccurKardia reposted this
Join us at the HITLAB Innovators Summit 2024 as our Chief Product Officer, Moin Hussaini, takes the stage to share insights on a groundbreaking topic: “Screening Health System ECGs for Undiagnosed Aortic Stenosis to Enable Earlier Intervention and Improved Outcomes.” 🗓️ Date: Tuesday, December 3, 2024 📍 Location: Microsoft Tech Center, NYC ⏰ Session Time: 2:30 PM Discover how AccurKardia is leveraging advanced AI-driven ECG interpretation to revolutionize cardiac care. Our mission is to enhance early detection, improve patient outcomes, and save lives through innovative solutions like AccurECG and AK-AVS. 💡 Don’t miss this opportunity to learn about the future of diagnostics and how we’re addressing one of cardiology’s greatest challenges: Aortic Stenosis. We can’t wait to connect with you in person. Let’s shape the future of healthcare together! #HITLABSummit #DigitalHealth #HealthTech #BetterOutcomes #Innovation
-
-
AI is transforming healthcare, and as this Washington Post editorial highlights, it’s a revolution that’s ultimately good for humanity. From improving diagnostic accuracy to expanding access to care, AI is helping address some of the biggest challenges in medicine. We invite you to explore this thought-provoking piece and join the conversation about how AI is reshaping healthcare for the better. https://lnkd.in/e8HVdB4u
Opinion | This year, be thankful for AI in medicine
washingtonpost.com
-
This Thanksgiving, we at AccurKardia want to take a moment to express our heartfelt gratitude. We are deeply thankful for the incredible dedication and hard work of the entire AccurKardia team, whose commitment drives our mission to transform ECG data into a more powerful diagnostic and broad biomarker. We are equally grateful to our collaborators, advisors, research partners, and commercial partners for their invaluable support and trust in our journey. Your contributions have been vital in advancing innovation and improving patient care. Wishing everyone a Happy Thanksgiving filled with joy, gratitude, and togetherness. Here’s to continuing our shared journey to make a lasting impact in human lives. #HappyThanksgiving #Gratitude #AccurKardia #Innovation #Healthcare
-
-
Join us at the HITLAB Innovators Summit 2024 as our Chief Product Officer, Moin Hussaini, takes the stage to share insights on a groundbreaking topic: “Screening Health System ECGs for Undiagnosed Aortic Stenosis to Enable Earlier Intervention and Improved Outcomes.” 🗓️ Date: Tuesday, December 3, 2024 📍 Location: Microsoft Tech Center, NYC ⏰ Session Time: 2:30 PM Discover how AccurKardia is leveraging advanced AI-driven ECG interpretation to revolutionize cardiac care. Our mission is to enhance early detection, improve patient outcomes, and save lives through innovative solutions like AccurECG and AK-AVS. 💡 Don’t miss this opportunity to learn about the future of diagnostics and how we’re addressing one of cardiology’s greatest challenges: Aortic Stenosis. We can’t wait to connect with you in person. Let’s shape the future of healthcare together! #HITLABSummit #DigitalHealth #HealthTech #BetterOutcomes #Innovation
-
-
Check out this insightful discussion on how ECG innovations are shaping the future of healthcare. Thank you, Jake Fishman and Cardiac Wire, for shedding light on this critical topic!
AI studies are showing that there's so much more we can do with ECG, and the first strep might be ECG-based aortic stenosis detection. Check out this interview with AccurKardia’s Juan C Jimenez and Moin Hussaini on ECG’s potential to serve as a broad biomarker – far beyond arrhythmia detection. https://lnkd.in/gbe9HWaD
The Cardiac Wire Show - Expanding ECG-Based Detection with AccurKardia
https://www.youtube.com/
-
What an incredible experience at the American Heart Association Scientific Sessions 2024 (#AHA24)! The AccurKardia team was honored to participate in the Health Innovation Pavilion and share insights on the future of cardiac diagnostics and innovation. A special thank you to the AHA Center for Health Technology & Innovation (#CHTI) for inviting us to speak and participate in this inspiring event. It was a privilege to connect with clinicians, innovators, and industry leaders, and to discuss how we’re leveraging ECGs as powerful biomarkers to improve cardiac care. From insightful sessions to impactful conversations, we’re leaving energized and more committed than ever to advancing innovation in heart and brain health. We’re proud to have shared this journey with such a dynamic community. Thank you, AHA, for a truly memorable event! #HeartHealth #HealthInnovation #HealthTech #BetterOutcomes
-